Evidence map›Paper›PMID 35565432›Full record

ArticleCancers2022

LDH-A-Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses.

Masahiro Shindo, Masatomo Maeda, Ko Myat, Mayuresh M Mane, Ivan J Cohen, Kiranmayi Vemuri, Avi S Albeg, Inna Serganova, Ronald Blasberg

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Masahiro ShindoDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Masatomo MaedaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.ORCID 0000-0002-5825-5378
Ko MyatDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Mayuresh M ManeDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Ivan J CohenMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kiranmayi VemuriDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Avi S AlbegDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Inna SerganovaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.ORCID 0000-0003-3561-8663
Ronald BlasbergDepartment of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 52, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · USRutgers, The State University of New Jersey · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Imaging tumor and T cell responses to metabolic and immune modulation therapyR01CA215136 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KOUTCHER, JASON ARTHUR, MERGHOUB, TAHA · 2017 to 2021
$3.8M
Imaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5M
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survivalR01CA163980 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BLASBERG, RONALD GEORGE, PONOMAREV, VLADIMIR · 2012 to 2016
$2.5M
Exploiting tumor metabolism to optimize T cell therapyR50CA221810 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Inna Serganova · 2018 to 2026
$1.6M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA163980NCI NIH HHS R01 CA204924NCI NIH HHS R01 CA215136NCI NIH HHS R50 CA221810
6 · The paper itself

Abstract

Three murine glioma cell lines (GL261, CT2A, and ALTS1C1) were modified to downregulate the expression of the murine

Indexed as

glioblastomaimmune-competent and incompetent host animalsLDH-A and LDH-B immunohistochemistryLDH-A shRNA knock-downLDH isoenzymestumor growth

Identifiers

PMID35565432
PMCPMC9100845
OpenAlexW4229003314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.